European equities opened on a firmer note Monday, with the Stoxx 600 up 0.68% to 565.90 by 8:35 a.m. in London, as most sectors turned green despite a pullback in defense names.
Germany’s DAX led gains, climbing 1.24% to 23,378.02, while Spain’s IBEX 35 added 1.13% to 16,001.00. In France, the CAC 40 rose 0.59% to 8,030.04, and London’s FTSE 100 gained 0.53% to 9,590.35. The outlier was Italy’s FTSE MIB, which slipped 0.12% to 42,611.18.
Pharma was the bright spot. Bayer AG surged 11%, topping the leaderboard after revealing strong Phase III trial results for Asundexian, its next-gen stroke prevention drug.
Investors cheered the data, hoping the blood thinner can compete with blockbusters like Eliquis and Xarelto.
AstraZeneca also edged 0.2% higher after confirming a massive $2 billion investment into its biologics plant in Frederick, Maryland, part of a $50 billion U.S. expansion plan revealed on Friday.
Meanwhile, Ubisoft’s stock surged 15% in Paris, their biggest rally since December 6, after the company finalized a €1.16 billion ($1.3 billion) cash injection from Tencent.
The deal gives Tencent a stake in Ubisoft’s Vantage Studios, a division spun out to focus on AAA franchises like Assassin’s Creed and Far Cry, and will help the French publisher pay down debt.
On the flip side, defense stocks were under pressure, with Rheinmetall down 2.7%, Renk off 2.9%, Hensoldt losing 2.1%, and Saab down 1.6%, as traders reacted to ongoing Ukraine-Russia peace talks.
A draft proposal seen as too lenient toward Moscow has rattled investors betting on prolonged military spending.
Europe’s Aerospace and Defense Index slipped 0.8%, the only major sector in the red.